Corporate Profile

Cidara is a clinical stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. Our first product candidate is CD101 IV, a once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. Our second product candidate is CD101 topical, a topical formulation of CD101 being developed as the first echinocandin for the treatment of vulvovaginal candidiasis, or VVC, and for the prevention of recurrent VVC, or RVVC. In addition, we have developed Cloudbreak™, a proprietary immunotherapy technology platform which we are using to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease.

Stock Information

CDTX (Common Stock)
PriceChange% ChangeVolume
$11.29 - 0.332.84%23,564
Previous CloseToday's OpenIntraday HighIntraday Low
Exchange: NASDAQ (US Dollar)
08/24/16 4:00 p.m. ET
Refresh quote


Stock chart for: CDTX.O.  Currently trading at $11.29 with a 52 week high of $18.07 and a 52 week low of $9.48.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources